Table 2.
Baseline patient characteristics
| All patients (n=209) | ||
|---|---|---|
| Median age at diagnosis, yr (range) | 63 (45–83) | |
| Sex (male, female) [n (%)] | 205, 4 (98, 2%) | |
| Stage IIIB, IV [n (%)] | 61, 148 (29, 71%) | |
| ECOG scale performance status [n (%)] | 0 | 42 (20) |
| 1 | 115 (55) | |
| 2 | 46 (22) | |
| 3 | 6 (3) | |
| 4 | 0 (0) | |
| Histological subtype [n (%)] | Adenocarcinoma | 81 (39) |
| Squamous cell carcinoma | 49 (23) | |
| Non-small cell lung cancer, NOS | 65 (31) | |
| Large cell carcinoma | 7 (3) | |
| Others | 7 (3) | |
| Highest pain level at diagnosis (before initiation of chemotherapy) [n (%)] | None (level 0) | 42 (20) |
| Mild (level 1–3) | 26 (12) | |
| Moderate (level 4–6) | 46 (22) | |
| Severe (level 7–10) | 95 (46) | |
| Pain level of the entire cohort at diagnosis (before initiation of chemotherapy) | Median, level 6 | |
| Opioid requirement at diagnosis, OME day−1 (before initiation of chemotherapy) [n (%)] | None (0 mg day−1 OME) | 77 (37) |
| Minimal (0.01–4.99 mg day−1 OME) | 44 (21) | |
| Moderate (5–29.99 mg day−1 OME) | 48 (23) | |
| High (≥30 mg day−1 OME) | 40 (19) | |
| Opioid requirement of entire cohort at diagnosis (before initiation of chemotherapy) | Average, 28.7 mg day−1 OME Median, 2.6 mg day−1 OME |
|